Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06296706

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Updated on 2024-11-14

630

Participants Needed

1

Research Sites

170 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This trial is a multicenter, randomized, controlled phase Ш clinical study of comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with previous first-line treatment failure.

CONDITIONS

Official Title

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years (inclusive) at the time of signing consent
  • Histologically or cytologically confirmed gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction
  • Locally advanced or metastatic disease progressed after first-line platinum/fluorouracil based chemotherapy, with or without immunotherapy
  • Disease progression confirmed by imaging during or after last systemic treatment
  • At least one measurable lesion by RECIST V1.1 not previously irradiated or showing progression after radiotherapy
  • Positive Her-2 expression patients must have received anti-Her-2 therapy; unknown status must be determined before enrollment
  • Adequate function of main organs
  • ECOG performance status of 0 or 1
  • Expected survival of 3 months or more
  • Female participants of childbearing potential must have a negative pregnancy test within 7 days before randomization and agree to use contraception through 6 months after last dose; males must agree to contraception and avoid sperm donation
  • Ability to understand the trial and provide written informed consent
Not Eligible

You will not qualify if you...

  • History of other active malignancies within 5 years (except certain cured local tumors like skin basal cell carcinoma, in situ carcinomas)
  • Uncontrolled serous cavity effusion requiring frequent drainage or intervention within 14 days before randomization
  • Central nervous system metastases
  • Prior use of paclitaxel or docetaxel unless progression occurred more than 1 year after neoadjuvant/adjuvant treatment
  • Known dMMR/MSI-H status without prior immunotherapy; unknown status must be clarified before enrollment
  • Serious cardiovascular or cerebrovascular disease including significant arrhythmias, recent major cardiac events, NYHA class II or higher, low LVEF, prolonged QTc interval, or poorly controlled hypertension
  • History of gastrointestinal perforation or fistula within 6 months before randomization
  • Active hepatitis B, hepatitis C, or HIV infection
  • Severe infections requiring systemic antimicrobial therapy within 14 days
  • Tuberculosis treatment within 2 years
  • Gastrointestinal obstruction or active inflammatory bowel disease within 28 days
  • Unresolved toxicities from prior treatments above grade 1 (except some non-safety risks)
  • Major surgery or invasive intervention within 28 days or planned tumor resection during study
  • Recent chemotherapy, immunotherapy, hormone therapy, targeted therapy, or experimental treatments within specified washout periods
  • Use of strong CYP3A4 inhibitors or inducers within 14 days
  • Allergy or contraindication to albumin, docetaxel, or glucocorticoids
  • Psychiatric or neurological disorders affecting adherence or history of drug/alcohol dependence
  • Participation in other interventional clinical trials concurrently
  • Other investigator-determined factors making participation unsuitable

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CSPC Zhongqi Technology(SJZ) Ltd

Shijiazhuang, Hebei, China, 050035

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Information Group officer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | DecenTrialz